Innovative Therapies for HER2-altered Non-Small Cell Lung Cancer: a Narrative Review.
HER2-directed therapies have transformed the treatment landscape of breast and gastric cancers, but targeting HER2 alterations in non-small cell lung cancer (NSCLC) has proven more challenging. HER2 mutations, found in 2-4% of NSCLC cases, define a unique molecular subset characterized by poor responses to conventional...